EpiCept Updates On Post-approval Commitments Regarding Ceplene
EpiCept said that Ceplene is approved in the EU for remission maintenance and prevention of relapse in adults with acute myeloid leukemia (AML) in first complete remission. EMA
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.